Potential Association of the Oral Microbiome with Trimethylamine N-Oxide Quantification in Mexican Patients with Myocardial Infarction

Table 1

Summary of cohort characteristics.

	Total (N = 16)	Without risk factor (N = 6)	Risk factor (N = 10)	p Value
Trimethylamine N-oxide (nmol/mL)^a	0.86 (0.53–1.45)	0.94 (0.79–1.66)	0.84 (0.33–1.25)	0.588
Age (years)	61 (36–78)	67 (48–78)	59 (36–70)	0.302
Men, n (%)	15 (93.7)	5/6	10/10	0.375
Patient medical history
Diabetes, n (%)	5 (31.2)	Non	5 (50)
Hypertension, n (%)	7 (43.7)	Non	7 (70)
Dyslipidemia, n (%)	3 (18.7)	Non	3 (30)
Current smoking, n (%)	4 (25)	Non	4 (40)
Clinical features
Killip–Kimball > 2	3 (18.7)	Non	3 (30)	0.25
MACE, n (%)	4 (25)	Non	4 (40)	0.234
TIMI ≥ 2n (%)	10 (62.5)	3 (50)	7 (70)	0.607
Affected blood vessels ≥ 2n (%)	11 (68.7)	3 (50)	8 (80)	0.299
Anterior descending, n (%)	13 (81.2)	3 (50)	10 (100)
Circumflex, n (%)	8 (50)	3 (50)	5 (50)	1.000
Right coronary, n (%)	11 (68.7)	4 (66.7)	7 (70)	1.000
Body mass index^a	26.9 (25.6–28.7)	28.6 (27.0–32.9)	26.5 (25.2–27.8)	0.221
Biochemical markers
cTnI (ng/mL)^a	32.9 (4.25–260.9)	441.8 (23.7–4101.0)	11.8 (2.3–69.6)
Total cholesterol (mg/dL)^a	164.1 (133.3–175.3)	179.3 (159.5–232.3)	152.4 (131.0–165.0)	0.104
HDL (mg/dL)^a	35.5 (28.5–43.3)	31.5 (31.4–38.3)	35.5 (28.2–50.2)	0.664
LDL (mg/dL)^a	94.9 (88.0–124.9)	137.2 (112.5–171.1)	91.9 (86.4–95.6)
Triglycerides (mg/dL)^a	138.5 (112.7–170.8)	131.5 (112.7–170.3)	143.1 (97.1–182.0)	0.958
Atherogenic index^a	3.05 (2.4–4.3)	4.5 (3.4–4.89)	2.6 (1.9–3.09)
Glucose (mg/dL)	127 (115.5–157.5)	125 (116.0–136.0)	129 (115.0–212.0)	0.786

^aMedian (IQR), p value Mann–Whitney or Fisher’s exact test. MACE: major adverse cardiovascular event, TIMI: thrombolysis in myocardial infarction score. cTnI: cardiac troponin I, HDL: high-density protein, LDL: low-density protein. .